secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124583
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251
--------------------------------------------------------------------------------

- Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.
- FDA cleared IND for DYNE-101 in DM1; Phase 1/2 ACHIEVE trial fully enrolled through 6.8 mg/kg Q8W cohort (56 participants).
- New ACHIEVE data (splicing, vHOT, functional measures) expected early January 2025; pursuing accelerated approval using splicing surrogate.
- Enrolling 20 mg/kg Q4W registrational cohort (n=32) in DELIVER trial for DMD exon 51; seeks accelerated approval based on dystrophin.
- Cash $723.7M at Sept 30, 2024; expected to fund operations at least into H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/0000950170-24-124583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/dyn-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer